Adverse Drug Reactions Associated with Anti-Tuberculosis Therapy by Kalaiselvan, Vivekanandan et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Adverse Drug Reactions 
Associated with Anti-Tuberculosis 
Therapy
Vivekanandan Kalaiselvan, Shatrunajay Shukla,  
Santhanakrishnan Ramesh Kumar, Nikita Mishra, 
Pawan Kumar and Rajeev Singh Raghuvanshi
Abstract
The pharmacovigilance has been evolved as a professional and ethical practice in 
ensuring the safety of medicines. The Adverse Drug Reactions (ADRs) associated 
with the use of medicines including Anti-Tuberculous Therapy (ATT) through a 
robust system of pharmacovigilance helps in promoting the safety of patients at 
large. The occurrence of ADRs associated with the use of ATT is expected, a large 
number of medicines are combined and used for prolonged duration. The suspected 
ADRs associated with first line ATT are well documented. However, the drugs used 
in second line or multidrug resistant to tuberculosis (TB), namely bedaquiline, 
reported to cause QT prolongation in electrocardiogram reading as one of the most 
common ADRs. Therefore, early identification and prevention of ADRs during ATT 
is essential for promoting the rational use and reduce the burden of anti-microbial 
resistance, besides achieving better treatment outcomes.
Keywords: Adverse Drug Reactions, Anti-Tuberculosis Therapy, Bedaquiline, 
Pharmacovigilance
1. Introduction
The unfortunate tragedy of thalidomide, in 1962, triggered the emergence 
and implementation of pharmacovigilance across the globe [1]. Thalidomide was 
introduced in Germany in 1957 and was widely prescribed for the treatment of 
morning sickness and nausea in pregnant women. Later it was found that babies 
were born with shortened or absence of limbs (medically known as phocomelia). In 
1962, thalidomide was discontinued from the market due to the increased number 
of scientific reports describing numerous cases of phocomelia [2]. This tragedy led 
to the creation of the World Health Organization (WHO) pilot research project for 
International Drug Monitoring in 1968, with the purpose to develop a system and 
tools applicable internationally, for detecting previously unknown or poorly under-
stood adverse drug reactions (ADRs) of medicines [3]. Currently, this network has 
been expanded to more than 140 developed, low- and middle-income countries. 
These 140 countries participated in the WHO programme for international drug 
monitoring as member states, and 31 countries have also joined as associate member 
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states. These countries have established pharmacovigilance system at their capacity, 
to monitor the medication safety. WHO and its collaborating centres are continu-
ously providing technical support for capacity building and strengthening of these 
pharmacovigilance systems [4].
As per WHO, Pharmacovigilance is defined as a “science of detection, assess-
ment, understanding and prevention of ADRs or any other drug related prob-
lems” [5]. This enables the scope of clinical practice of monitoring & reporting 
of ADRs, analyses the information and sharing the learnings with healthcare 
providers for prevention of such ADRs, for better patient’s safety and outcomes. 
Pharmacovigilance and its concepts are evolving as one of the most important 
components in contemporary clinical and regulatory practice. In clinical trials, 
most medicines will only be tested for short-term safety and efficacy on a limited 
number of carefully selected individuals (excluding pregnant women, children and 
elderly). In some cases, as few as 500, and rarely more than 5000, subjects receive 
the investigational new drug prior to its release [6]. It is not possible to identify 
and record many ADRs in such a shorter duration, protected environment and 
restricted population in trials. After stage three of clinical trial, the medicine is 
available to be launch in the market and is legally set free for consumption by the 
general population. Post market experience has shown that many adverse effects, 
interactions (i.e. with foods or other medicines), and risk factors may come to light 
even after several years of introducing the medicine into the market [7]. Moreover, 
many studies have shown that an ADR may result into a significantly decrease in 
the quality of life, increased hospitalizations, prolonged hospital stay and mortality 
[8]. Therefore, monitoring the safety of the medicines throughout its life period is 
pivotal, as most of the ADRs are usually reported during prolonged use.
The pharmacovigilance practice applies equally to medicines used in public 
health programs, including medicines used in Anti-Tubercular Therapy (ATT). As 
the management of tuberculosis (TB) involves longer duration of therapy and also 
multiple drugs, these arise as predisposing factors for the occurrence of ADRs [9]. 
Such ADRs pose a challenge in the management of TB. Though it is a prolonged 
treatment, medication must be continued in order to ensure the compliance, 
otherwise it will end with treatment failure or developing antimicrobial resistance 
[10]. Generally, patients discontinue the medication due to the emergence of ADRs 
resulting from the administration of first-line anti-TB drugs. During the course of 
TB treatment, there may be a risk of morbidity and mortality, particularly with 
drug-induced hepatitis. Therefore, there are public health program in various coun-
tries that systematically monitor, prevent and manage ADRs encountered during 
the treatment of TB, in order to achieve maximum treatment outcomes [11].
TB is a chronic infection caused primarily by Mycobacterium tuberculosis. The 
lung is generally the first affected organ, as the infection is usually due to inhala-
tion of infected droplet nuclei. Approximately 80% of the TB cases are pulmonary 
TB [12]. Around 30% patients who are infected with Human Immune Deficiency 
Virus (HIV) will also develop active tuberculosis. Factors, such as HIV, Resistant 
TB, drug–drug interactions raise the complexity of problem. As per the WHO 
strategy, directly observed treatment short-course (DOTS) therapy for the duration 
of 6–8 months is one of the important components for the treatment of TB. The 
short-course therapy is usually performed in 2 phases: the initial phase (2 months) 
involves the concurrent use of at least 3 drugs to rapidly reduce the bacterial popu-
lation and prevent emergence of drug-resistant bacteria. The second, continuation 
phase, (4–6 months) involves fewer drugs and is used to eliminate any remaining 
bacteria and prevent recurrence. Worldwide, HIV infection has been identified 
as an important predisposing factor of immune-suppression leading to TB [13]. It 
increases the susceptibility to primary infection and increases the reactivation rate 
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of TB [14]. Although this regimen is effective in treating active TB, it is associated 
with many ADRs and poses a significant challenge to completion of treatment. 
Recommended treatment regimens for TB are given in Table 1.
2. Importance of ADR reporting in tuberculosis
Multiple types of drug therapy are given for TB, and even new TB patients 
(sensitive to first-line drugs), are receiving a treatment regimen with a combina-
tion of four drugs [15]. There is a chance for developing ADR either for one or the 
combination of drugs, and that has to be identified for ensuring a sustained treat-
ment compliance, till the completion of ATT. When treatment is given to patients 
with TB-associated drug resistance, either ionized resistance, multidrug resistance 
or rifampicin resistance, pre-extensively drug resistance or extensively drug 
resistance TB, the number of drugs given could be higher, and it becomes impera-
tive to identify the resulting/associated ADRs. In case any ADR takes place, the 
treatment management has to be done appropriately [16]. For TB patients having 
HIV co-infection, the treatment given for HIV infection, including the antiretrovi-
ral therapy, and/or the medication given for the associated conditions, may overlap 
with the ADR presented, and so it becomes very important to monitor this group of 
population for efficient management. In addition, also in TB patients with special 
medical conditions associated, like associated diabetes mellitus, liver, renal or sei-
zure disorders, and psychosis, the treatment should be done cautiously, by closely 
observing the progress and monitoring all the ADRs encountered. Furthermore, 
when new drugs like Bedaquiline (BDQ ), Delamanid (DLM) and Pretomanid 
are initiated at TB programs, it is essential that the associated ADRs are captured 
promptly for effective management of TB [17].
First line drugs given for Drug Sensitive TB New patients with pulmonary TB should receive a 
regimen containing 6 months of rifampicin:
(Isoniazid + Rifampicin + Pyrazinamide + Ethambutol)
*In populations with known or suspected high levels of 
isoniazid resistance, new TB patients may receive HRE 
as therapy in the continuation phase.
Recommended:
1. Daily dosage
2. Fixed Dose Combination drugs
Second line drugs given for Rifampicin 
Resistance/Multi Drug Resistance/Extremely 
Druf Resistance (RR/MDR/XDR) TB and 
Multi Drug Resistance (MDR-TB)
Group A: Fluoroquinolones
Levofloxacin, Moxifloxacin, Gatifloxacin
Group B: Second-line injectable agents
Amikacin, Capreomycin, Kanamycin, (Streptomycin)
Group C: Other core second-line agents
Ethionamide/prothionamide, Cycloserine/terizidone, 
Linezolid, Clofazimine








Recommended drugs used to treat tuberculosis.
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2.1 ADRs associated with first-line anti-TB drugs
The ATT is expected to cause more ADRs, because it involves combination of 
several medicines and is used for a longer duration [9]. One of the most common 
ADRs observed with the administration of ATT is gastrointestinal symptoms, such 
as nausea, vomiting etc. These ADRs could be symptomatically managed without 
the need for a change in the dosage of drugs. The hepatotoxicity is also a risk associ-
ated with ATT, and its frequency can range from 2–39% in different countries [18]. 
As compared to Western population, Indian sub-population studies reported high 
incidence of hepatotoxicity with ATT [19].
2.1.1 Isoniazid
Isoniazid has been shown to be well tolerated at recommended dose. However, 
systemic or cutaneous hypersensitivity reactions can occasionally occur during 
the first weeks of treatment [15]. By daily supplementary dose of pyridoxine in 
vulnerable patients, the risk of peripheral neuropathy can be excluded. In the later 
stages of treatement, some susceptible patients can develop neurological distur-
bance, encompassing optic neuritis, toxic psychosis and generalized convulsions. 
This may require the discontinuation of isoniazid. An uncommon but potentially 
serious reaction is symptomatic hepatitis, which could be precluded by prompt 
withdrawal of treatment. Asymptomatic rise in serum concentrations of hepatic 
transaminases at the beginning of treatment has very low clinical significance. 
The same resolves spontaneously as the treatment carry on. Other rare adverse 
effects linked with isoniazid are lupus-like syndrome, pellagra, anemia, and 
arthralgias [20].
2.1.2 Rifampicin
At currently recommended doses, this drug has been shown to be well tolerated 
by most of the patients. Occasionally it may cause gastrointestinal reactions includ-
ing abdominal pain, nausea, vomiting and pruritus with or without rash [21]. With 
an intermittent drug administration, adverse effects, such as fever, influenza-like 
syndrome and thrombocytopenia may occur. In HIV-positive TB patients, exfolia-
tive dermatitis is more common. Patients taking the drug 3 times a week, adverse 
effects including temporary oliguria, dyspnoea and haemolytic anemia have 
been reported. If the regimen is changed to daily dosage these reactions usually 
subsided. In the beginning of treatment, moderate rises in serum concentrations 
of bilirubin and transaminases are common adverse effects are often transient 
and not clinical significant. A potentially fatal condition is dose-related hepatitis, 
it is therefore important to not exceed the maximum recommended daily dose 
of 600 mg.
2.1.3 Pyrazinamide
This drug has been reported to cause various skin reactions, like maculopapular 
rash, erythema multiforme, exfoliative dermatitis and drug rash with eosinophilia 
and systemic symptoms (DRESS) syndrome. Among the first-line drugs, pyra-
zinamide has shown to be the most common drug to cause cutaneous ADRs [22]. 
Pyrazinamide may cause gastrointestinal intolerance. Hypersensitivity reactions are 
rare, but have been reported in some patients with modest flushed skin. During the 
early phases of the treatment, moderate rises in serum transaminase concentrations 
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are common. A rare complication is severe hepatotoxicity. A degree of hyperuri-
caemia may also occur asymptomatically as a result of inhibition of renal tubular 
secretion [15]. The treatment may also result into gout, which can be treated with 
allopurinol. Arthralgia, especially of the shoulders, may occur which can be treated 
with simple analgesics (especially aspirin). By prescribing regimens with inter-
mittent administration of pyrazinamide, hyperuricaemia and arthralgia may be 
eliminated. Sideroblastic anemia and photosensitive dermatitis are some of the rare 
ADRs associated with this drug [7, 8].
2.1.4 Streptomycin
Streptomycin injections are painful, and rash, induration, or sterile abscesses 
can be formed at injection sites. Numbness and tingling around the mouth occur 
immediately after injection and cutaneous hypersensitivity reactions can occur. The 
incidence of ototoxicity associated with the use of ATT may be as high as 25% [23]. 
With currently recommended doses, the complications like impairment of vestibu-
lar function are uncommon. Vertigo is more common than hearing loss. Indications 
of injury at the 8th cranial (auditory) nerve include ringing in the ears, ataxia, 
vertigo and deafness. The damage is impermanent and can be reversed by reducing 
in dosage, or the stopping the treatment with this drug. This damage is commonly 
occurs within the first 2 months of treatment. More commonly, the other aminogly-
coside antibiotics e.g. kanamycin, amikacin and capreomycin are more nephrotoxic 
than streptomycin. If urinary output falls, albuminuria occurs, or tubular casts are 
detected in the urine, streptomycin should be stopped, and renal function should 
be evaluated.
Though WHO’s recommendation is not to use injectable streptomycin, we 
should take into consideration that other recommended treatments with aminogly-
cosides may cause similar types of ADRs [17].
2.1.5 Ethambutol
Dose-dependent optic neuritis caused by Ethambutol can result in impairment 
of visual acuity and color vision in one or both eyes. Early changes are usually 
reversible, but blindness can occur if treatment is not discontinued promptly. 
Ocular toxicity is rare when ethambutol is used for 2–3 months at recommended 
doses. Peripheral neuropathy has been reported in approximately 20% of patients 
treated with ethambutol. Other rare adverse events include generalized cutaneous 
reaction, arthralgia and, very rarely, hepatitis [24].
Several studies have reported that the drugs used to treat TB may cause ADRs. 
Management and prevention of such ADRs are important measures to be adopted 
to increase tolerance. Generally, with non-serious ADRs, the drugs do not need 
to be stopped, while with serious ADRs, the drugs often have to be stopped and a 
modified regimen has to be implemented [9].
2.1.6 Capreomycin
This drug is administered in combination with other first-line drugs. The com-
mon ADRs reported are hypersensitivity reactions, including urticaria and rashes, 
nephrotoxicity, electrolyte disturbance, hearing loss wit tinnitus and vertigo [11].
Grading of toxicity associated with drugs used for TB treatment and the ADRs 
associated with the anti-TB drugs used for therapy are given in Tables 2 and 3, 
respectively.
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Adverse Drug Reaction Symptoms and signs Responsible Drug
Audiovestibular 
manifestations





Dizziness, sweating, fainting, poor 
response to infections
Fluorquinolones (FQ ), Rifampicin 
(R), Pyrazinamide (Z)








Hematology Leucopenia, thrombocytopenia, 
anemia, eosinophilia
Rifampicin (intermittent); Linezolid, 
Isoniazid, capreomycin
Hepatitis Anorexia, nausea, vomiting, 
jaundice, abdominal pain
Isoniazid, Rifampicin, Ethambutol, 
Pyrazinamide
Hypothyroidism Fatigue, weight gain, depression P-aminosalicylic acid, pro/
Etionamide








Peripheral neuropathy Numb feet or hands Ionizedlinezolid; Cycloserine, 
Aminoglycosides
Renal impairment Uraemia; haematuria Aminoglycosides, Capreomycin; 
Rifampicin (intermittent)
Visual disorders Vision loss and color blindness; 
uveitis
Ethambutol, Linezolid; Rifabutin, 
Rifapentane;
Table 3. 
Most common ADRs associated with the use of anti-TB drugs.
2.2 ADRs associated with second-line anti-TB drugs
Resistant -TB is usually treated with a combination of drugs that are more toxic 
than isoniazid and rifampicin. These drugs include fluoroquinolones, aminogly-
cosides, ethionamide, cycloserine, aminosalicyclic acid, linezolid and clofazimine, 
among others [26]. The main ADRs associated with the use of cycloserine are 
reported as neurological disorders, including headache, dizziness, vertigo, drowsi-
ness, tremor, convulsions, confusion, psychosis, depression, rashes, allergic derma-
titis, megaloblastic anemia, and changes in liver function tests [27]. Minor adverse 
Grade & Level Toxicity
1 - Mild Transient or mild discomfort; no limitation in activity; no medical intervention or 
therapy required.
2 – Moderate Mild to moderate limitation in activity, some assistance may be needed; none or 
minimal medical intervention or therapy required.
3 - Severe Marked limitation in activity, some assistance usually required; medical intervention or 
therapy required, hospitalization is possible.
4 – Life 
threatening
Extreme limitation in activity, significant assistance required; significant medical 
intervention or therapy required, hospitalization or hospice care are probable.
Table 2. 
Grades of toxicity resulting from TB treatment [25].
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effects are relatively common, and they can be easily managed with symptomatic 
treatment. However, some adverse effects can be life-threatening, for example, 
nephrotoxicity due to aminoglycosides, cardiotoxicity due to fluoroquinolones, 
gastrointestinal toxicity due to ethionamide or para-amino-salicylic acid, central 
nervous system toxicity due to cycloserine, etc. [17].
2.3 Multi Drug-resistant TB (MDR-TB)
MDR-TB is caused by organisms that are resistant to isoniazid and rifampicin. As 
per the WHO reports, an estimated 480 000 worldwide patients developed MDR-TB 
in 2015, in addition to the 100 000 patients with rifampicin-resistant TB that were 
newly eligible for MDT-TB treatment [22]. Again, according to WHO, the second 
highest MDR-TB incident country in the world, China, accounted for 45% of the 580 
000 cases, together with Indian and the Russian Federations, with 6.6% of new TB 
cases and 30% of previously treated cases having MDR/Rifampicin resistant TB.
The novel anti tubercular drugs, namely BDQ and DLM, now included in WHO 
second-line treatment [28], as well as in some countries, have received conditional 
approval for use in adults with MDR-TB. BDQ, a new anti TB- drug, has been given 
approval by the United States Food and Drug Administration in 2012 [29], and by 
the European Medicines Agency in 2014. In India, BDQ was introduced under the 
conditional access program in 2015. The safety profile and tolerability of a BDQ-
containing treatment regimen used in India has been established. QT prolongation 
in electrocardiogram reading has been reported as one of the most common ADRs 
with the use of BDQ; the others include peripheral neuropathy, vomiting, breath-
lessness and thrombocytopenia [30].
2.4  Prevalence of adverse events associated with second-line anti-TB drugs in 
children
Children, especially those under 10 years old, can tolerate second-line combina-
tion of anti-TB drugs better than adults. In children, the higher rate of ADRs has 
been observed in those having HIV as comorbid infection, as compared to TB infec-
tion alone [14]. Several studies have also revealed that the majority of the adverse 
events found in children are mild to moderate, thus not requiring interruption or 
complete cessation of treatment. Moreover, even with the occurrence of few severe 
adverse events, permanent discontinuation of drugs is rarely necessary [14].
The second–line drugs are generally found to cause more ADRs, as compared to 
the first-line drugs [31]. The healthcare workers treating children should be aware 
of this fact and should thus be able to manage such ADRs. Healthcare workers, 
care givers or parents are required to be trained accordingly, because most of 
the children may not be able to report the drug-associated ADRs. The MDR-TB 
treatment outcomes in children are well achieved in many countries by using the 
currently available drugs [32, 33]. However, the improvement of the MDR-TB 
treatment programme can be achieved by: (1) implementing targeted or cohort 
event monitoring of adverse events, with the use of MDR-TB drugs in children; and 
(2) healthcare works training for a timely ADRs reporting, aiming to achieve the 
maximum treatment outcomes.
2.5  Causality and severity assessment of anti-TB drugs-associated adverse 
events
After determining the adverse events (suspected) of anti-TB drugs, the very next 
step is to establish the causal or temporal relationship between the drug and the 
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event, i.e., is the drug actually causing the event? It is possible that the administered 
drug and the occurrence of an adverse event may have a close temporal relationship, 
but still not be a reaction [34].
Having considered the parameters in assessing the temporal relationship, the 
next step is to address the following question: “Did these medicines actually cause 
the event?” In other words, “Is the event a reaction?” It is conceivable/acceptable that 
the administration of a medicine and the occurrence of an event may have a close 
relationship, but still not be a reaction, for example, death from myocardial infarc-
tion. In actual practice, the assessment of the relationship and causality frequently 
merge, particularly when an event is a well-known reaction and the relationship 
is close. The two phases occur without conscious deliberation, but should be there 
nevertheless. However, it is often necessary to gather other knowledge about the 
medicine, the patient and the event, in order to undertake a deliberate evaluation 
of these factors, which are actually external to the drug–event association that has 
occurred. Causality assessment is the methodological approach for evaluating a sig-
nal (identification of new safety alert) [35]. As per WHO, the causality assessment 
scale is the estimated strength of the relationship between the drug and the ADR 
can be classified as certain, probable, possible, unlikely, conditional/unclassified, 
Certain • Event of laboratory test abnormality, with plausible time relation-
ship to drug intake
• Cannot be explained by disease or other drugs
• Response to withdrawal plausible (pharmacologically, 
pathologically)
• Event definitive pharmacologically or phenomenological (An 
objective and specific medical disorders or a recognized pharma-
cological phenomenon)
• Rechallenge (if necessary)
Probable • Event or lab test abnormality, with reasonable time relationship 
during intake
• Unlikely to be attributed to disease or other drugs
• Response to withdrawal clinically reasonable
• Rechallenge not necessary
Possible • Event or laboratory test abnormality, with reasonable time 
relationship to drug intake
• Could also be explained by disease or other drugs
• Information on drug withdrawal lacking or unclear
Unlikely • Event or laboratory test abnormality with a time to drug that 
makes a relationship improbable (but not impossible)
• Diseases or other drugs provide plausible explanations
Conditional/unclassified • Event or laboratory test abnormality
• More data for proper assessment needed
• Or additional data under examination
Unassessable/Unclassifiable • A report suggesting an adverse reaction
• Cannot be judged because of insufficient or contradictory 
information
• Report cannot be supplemented or verified
Table 4. 
WHO’s scale for causality assessment [36].
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unassessable/unclassifiable (Table 4). The Naranjo scale can also be applied for 
causality assessment, and is algorithm-based (Table 5) [38].
The severity assessment of ADRs can also be categorized in to into seven levels 
of severity level 1 and 2 are considered less severe or mild, levels 3 and 4 are 
moderate, and levels 5, 6 and 7 are classified as severe [39]. Severe level of ADRs 
includes all potentially life threatening ADRs, and the ones causing permanent 
damage or requiring intensive medical care. Even some other assessment scales 
classify severe and lethal.
3. Conclusions
The emergence of ADRs continues to remain an important public health issue 
worldwide, as it is among the ten leading causes of mortality. Early identifica-
tion and prevention of ADRs during TB treatment will lead to the rational use of 
medicines and to a reduce burden of antimicrobial resistance. Better adherence 
within the target population will reassure that monitoring and good commu-
nication on risks and benefits provide favorable implications for decisions on 
medicine procurement. Safety monitoring of medicines is thus a vital and crucial 
element of any health system. As TB treatment relies on a multi-drug therapy for 
long duration, the emergence of ADRs is inevitable. Therefore, ADR reporting is 
essential as it will strengthen the evidence, maximize the benefits and minimize 
the risks.
S. No. Question Answer
Yes No Do Not Know
1 Are there previous conclusive reports on this reaction? +1 0 0
2 Did the adverse event appear after the suspected drug 
was administered?
+2 −1 0
3 Did the adverse reaction improve when the drug 
was discontinued or a specific antagonist was 
administered?
+1 0 0
4 Did the adverse reaction reappear when the drug was 
re-administered?
+2 −1 0
5 Are there alternative causes (other than the drug) that 
could solely have caused the reaction?
−1 +2 0
6 Did the reaction reappear when a placebo was given? -1 +1 0
7 Was the drug detected in the blood (or other fluids) in 
a concentration known to be toxic?
+1 0 0
8 Was the reaction more severe when the dose was 
increased, or less severe when the dose was decreased?
+1 0 0
9 Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure?
+1 0 0
10 Was the adverse event confirmed by objective 
evidence?
+1 0 0
The total score calculated from this table defines the category as:
a. Definite (>9).
b. Probable (5 to 8).
c. Possible (1 to 4).
d. Unlikely (< 0).
Table 5. 
Naranjo’s scale for causality assessment [37].
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